Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Drug Device Combination Products Market to Reach USD 379.17 Billion by 2030 | MarketsandMarkets™

globenewswire.com
ABT Abbott maintains a leading position with its Medical Devices segment, offering drug-eluting stents and drug-coated balloons. The company continues to expand its global footprint through innovation and strategic acquisitions, indicating strong growth potential. BSX BDX Becton Dickinson and Company is identified as a major company in the drug device combination products market. The article references their whitepaper on integration systems, but does not offer a specific sentiment for the company itself. LLY MDT Medtronic dominated the market in 2024 with combination therapies and significant R&D investment. Their extensive global operations and focus on drug-eluting stents, infusion pumps, and smart insulin pens position them strongly for continued market leadership. ABBV

Delray Beach, FL, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The global drug device combination products market is projected to reach USD 379.17 billion by 2030, from USD 243.02 billion in 2025, at a CAGR of 9.3% during the forecast period. The convergence of pharmaceuticals and medical technology is rapidly redefining how chronic diseases are treated worldwide.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131140423

Market Overview: What is Driving Growth and Why It Matters Now

Drug-device combination products—integrating therapeutic drugs with delivery devices such as insulin pens, autoinjectors, inhalers, wearable injectors, and drug-eluting stents—are becoming essential to modern healthcare delivery.

What is driving this acceleration? The answer lies in the rising prevalence of chronic diseases, an expanding geriatric population, and increasing demand for precise, patient-friendly drug delivery systems.

Why does this matter now for business leaders? Healthcare systems are under pressure to reduce hospital dependency, improve patient adherence, and manage long-term treatment costs—making combination products a strategic priority for pharmaceutical companies, medtech manufacturers, and investors alike.

In parallel, favorable reimbursement policies, enhanced healthcare infrastructure, and government initiatives supporting access to advanced therapeutics are strengthening market fundamentals globally.

Market Dynamics

Driver: Rising prevalence of chronic diseases

The growing global burden of diabetes, obesity, cancer, respiratory disorders, and cardiovascular disease is a primary catalyst for market expansion.

These conditions demand reliable, targeted, and user-friendly drug delivery. Combination products improve therapeutic precision, enable self-administration, and enhance adherence—directly influencing clinical outcomes and long-term healthcare costs.

Restraint: Stringent regulatory requirements

How does regulation impact market growth? Drug-device combination products must comply with both pharmaceutical and medical device regulations, creating complex and time-intensive approval pathways.

Agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require manufacturers to navigate overlapping frameworks. The FDA’s Office of Combination Products determines whether a product is regulated as a drug, device, or biologic—affecting whether Premarket Approval (PMA) or a New Drug Application (NDA) is required.

This regulatory complexity increases development costs and slows patient access, presenting a strategic challenge for global market players.

Opportunity: High-growth potential in emerging markets

Where is the next wave of growth expected? Emerging economies—particularly China, India, and Brazil—represent the most compelling expansion opportunity.

Rising healthcare expenditure, aging populations, and growing awareness of chronic disease management are driving rapid adoption of advanced combination products. Asia Pacific markets benefit from expanding healthcare infrastructure and comparatively lower production costs, offering attractive conditions for manufacturing investment and regional distribution.

For multinational corporations, these markets offer both volume growth and long-term strategic positioning in the evolving global healthcare ecosystem.

Challenge: Product malfunction and drug wastage

Product reliability remains a critical operational and reputational risk.

According to BD’s whitepaper, “The Value of an Integration System for Combination Products,” design flaws, poor component integration, and usability issues can lead to:

Regulators, including the FDA, have intensified oversight of malfunctioning products, further affecting approval timelines.

How are manufacturers responding? By prioritizing design optimization, system integration, and comprehensive user training to improve safety, reduce waste, and protect long-term commercial viability.

Market Ecosystem: Who Is Shaping the Industry

The market spans pharmaceutical companies, medical device manufacturers, contract development organizations, and regulatory authorities. Hospitals, pharmacies, healthcare providers, caregivers, and patients serve as critical end users.

Regulatory agencies such as the FDA and EMA enforce dual oversight, reinforcing the importance of compliance-driven innovation and cross-sector collaboration.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=131140423

Segment Insights

Injectable drug delivery devices lead the market

Injectable drug delivery devices held the largest market share in 2024. Autoinjectors, prefilled syringes, and pen injectors are widely adopted for biologics and advanced therapies requiring precision dosing.

Key growth factors include:

These advancements support patient-centric care models and reduce dependency on clinical settings.

Home care settings to record the highest CAGR

When and how are care models changing? Home care is expected to be the fastest-growing end-user segment during the study period.

Patients managing chronic diseases increasingly prefer home-based treatment to save time, reduce hospital visits, and lower costs. Portable autoinjectors, insulin wearables, and smart inhalers are enabling safe and effective self-care.

An aging population, institutional capacity constraints, and demand for personalized medicine are accelerating this structural shift.

North America leads market share

North America accounted for the largest market share in 2024 and is projected to maintain its leadership due to:

Major companies including Abbott, Becton Dickinson and Company, and Eli Lilly and Company continue to drive innovation from the US, supported by advanced healthcare infrastructure and strong adoption of new technologies.

Asia Pacific emerges as the fastest-growing region

China and India are expected to drive the highest demand growth, supported by chronic disease prevalence, expanding healthcare systems, and rising adoption of self-administration technologies.

Key Market Players

Leading companies in the global drug device combination products market include:

Abbott (US), Boston Scientific Corporation (US), Medtronic (Ireland), Becton, Dickinson and Company (US), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), AbbVie Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Stryker (US), B. Braun SE (Germany), Terumo Corporation (Japan), and Kaleo, Inc. (US).

The market remains consolidated, with top players leveraging global distribution networks, high R&D spending, and strong brand equity, while smaller firms compete through pricing strategies and targeted innovation.

Recent Industry Developments

Company Highlights

Abbott (US) maintains a leading position through its Medical Devices segment, offering drug-eluting stents and drug-coated balloons across cardiovascular and diabetes care. With R&D and manufacturing operations in over 100 countries and distribution in more than 160 markets, the company continues to expand its global footprint through innovation and strategic acquisitions.

Eli Lilly and Company (US) ranks second globally, supported by a biologics-focused pipeline and advanced injection systems for diabetes and other therapeutic areas. Operating in 14 countries with distribution across 125 markets, the company emphasizes digital delivery solutions such as the HumaPen smart insulin platform.

Medtronic (Ireland) dominated the market in 2024, backed by combination therapies including drug-eluting stents, implantable infusion pumps, and smart insulin pens. The company invested approximately USD 2.84 billion in R&D in fiscal year 2024 and operates in more than 160 countries.

Strategic Outlook for Decision-Makers

For CEOs, CFOs, CMOs, and healthcare strategists, the drug device combination products market represents a high-growth intersection of technology, therapeutics, and value-based care. Market success will increasingly depend on regulatory expertise, design excellence, emerging market penetration, and the ability to support decentralized healthcare models.

For more information, Inquire Now!

Discover Connected Healthcare Market Opportunities:

Injectable Drug Delivery Market

Pharmaceutical Drug Delivery Market

Autoinjectors Market

Injection Pen Market

Prefilled Syringes Market

Get access to the latest updates on Top Companies in Drug Device Combination Products and Drug Device Combination Products Market Size